Quick Answer
REGENXBIO Inc. reported Research And Development Expense of $228.30 million for the year ending 2025.
- REGENXBIO Inc. showed an increase of +9.5% in Research And Development Expense from 2024 to 2025.
- This data is from REGENXBIO Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 13 years of available data (2013 to 2025), REGENXBIO Inc.'s Research And Development Expense has grown by 4,419.9%.
- Historical annual values: Fiscal year 2025: $228.30 million | Fiscal year 2024: $208.52 million | Fiscal year 2023: $232.27 million | Fiscal year 2022: $242.45 million | Fiscal year 2021: $181.44 million | Fiscal year 2020: $166.29 million | Fiscal year 2019: $124.19 million | Fiscal year 2018: $83.87 million | Fiscal year 2017: $57.22 million | Fiscal year 2016: $45.48 million | Fiscal year 2015: $17.28 million | Fiscal year 2014: $4.96 million | Fiscal year 2013: $5.05 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: